Pamela L.Taylor (Pam)

Of Counsel

Chicago + 1.312.269.4327

Connect:

Share

Pam Taylor is an antitrust lawyer with more than 25 years of experience in antitrust and competition law issues, including the antitrust aspects of mergers, joint ventures, and government investigations. She represents clients in government antitrust investigations and enforcement actions before the Federal Trade Commission and the Department of Justice Antitrust Division. She also advises companies on antitrust issues in dealing with customers, suppliers, and competitors. Her practice includes advising on Hart-Scott-Rodino premerger notification requirements, joint ventures and strategic alliances, pricing and price discrimination, marketing practices, distribution issues, and dealer terminations.

Pam has provided antitrust advice to global companies on their distribution strategies for the United States.

Pam's experience includes matters in the pharmaceutical, medical device, hospital products, and veterinary products businesses. She also has advised global manufacturers and distributors across a wide range of industries including aerospace and defense, automotive, consumer products, chemicals, technology, food products, mining, and steel. Representative clients include Abbott Laboratories, Baxter International, Boehringer Ingelheim, Cardinal Health, Hill-Rom, Leggett & Platt, and Zekelman Industries. In addition, Pam has served as antitrust counsel to trade associations.

Pam is a member of the Illinois bar and serves on the board of the Legal Aid Society.

Experience

  • Riverside sells Red Nucleus to Thomas H. Lee PartnersJones Day represented The Riverside Company in its sale of Red Nucleus, an industry-leading integrated provider of learning and development, medical communications, market access, and R&D and clinical solutions to the life sciences industry globally, to Thomas H. Lee Partners.
  • The Aaron's Company agrees to be acquired by IQVenturesJones Day advised The Aaron's Company, Inc. in the acquisition and take private of Aaron’s by IQVentures Holdings, LLC, a leading fintech organization, for $10.10 per share in cash, or an enterprise value of approximately $504 million.
  • Metso USA acquires Screen Machine Industries, LLCJones Day represented Metso USA in its acquisition of Screen Machine Industries LLC, a manufacturer of heavy crushing and screening equipment for the mining, land clearing, and recycling industries.
  • Jones Day represents CITGO in court-ordered saleJones Day is representing CITGO in connection with the proposed court-ordered sale of CITGO by a Special Master appointed by the United States District Court for the District of Delaware to Amber Energy, backed by Elliott Investment Management.
  • Riverside acquires CloudpermitJones Day represented The Riverside Company in its acquisition and financing of Cloudpermit, a community development software company for local governments, citizens, and other stakeholders.
  • Riverside portfolio company acquires FleetWatcherJones Day represented The Riverside Company in connection with the acquisition and financing by portfolio company Align Technologies of FleetWatcher, LLC, a leading provider of fleet and materials management software.
  • Riverside-led investor group acquires The Townsend GroupJones Day advised The Riverside Company in the acquisition and financing of The Townsend Group, a leading provider of global investment management and advisory services focused exclusively on real estate and real assets, from Aon plc, a leading global financial services firm.
  • Blue Sea Capital sells Sunvair Aerospace Group to Greenbriar Equity GroupJones Day represented Blue Sea Capital LLC in the sale of Sunvair Aerospace Group, a leading maintenance, repair and overhaul ("MRO") services provider specializing in landing gear, avionics, flight instruments, sensors and cargo loading systems, to Greenbriar Equity Group.
  • Riverside sells Energy Exemplar to Blackstone and Vista Equity PartnersJones Day advised investment funds affiliated with Riverside's Australia Fund in connection with the sale of its Energy Exemplar platform to a newly formed acquisition vehicle jointly controlled by investment funds affiliated with Blackstone and Vista Equity Partners.
  • Swander Pace Capital sells Functional Formularies to DanoneJones Day advised Swander Pace Capital in the sale of Functional Formularies, a leading provider of organic, whole food, shelf-stable feeding tube formulas, to Danone.
  • Sanken Electric portfolio company receives $175 million investment from Niobrara and Prysm CapitalJones Day advised Sanken Electric Co Ltd. regarding the $175 million investment from Niobrara Capital Partners LP and Prysm Capital LLC as investors in subsidiary Polar Semiconductor LLC.
  • Riverside invests in KasewareJones Day advised The Riverside Company in its acquisition of Kaseware, a leading provider of investigation management software sold to public safety agencies and corporations.
  • MEDHOST sells company to N. Harris Computer CorporationJones Day advised MEDHOST, Inc., a leading electronic health record solution provider, in its sale of the company to N. Harris Computer Corporation, a wholly-owned subsidiary of Constellation Software, Inc.
  • Swander Pace Capital sells Patriot Pickle to H.I.G. CapitalJones Day advised Swander Pace Capital in the sale of Patriot Pickle, a manufacturer and distributor of high-quality refrigerated pickles across the United States to restaurant chains, supermarkets, and delis, to an affiliate of H.I.G. Capital.
  • Cortec Group sells Chauvet & Sons to Court Square Capital PartnersJones Day advised Cortec Group in the sale of its Chauvet & Sons platform to Court Square Capital Partners.
  • Curran Group sells Crossville, Inc. to AHF ProductsJones Day acted as Antitrust counsel to the Curran Group in its sale of assets of Crossville, Inc., a highly regarded brand in commercial and residential tile products, to AHF Products.
  • Timken acquires Des-CaseJones Day advised The Timken Company in the acquisition of Des-Case Corp., a Nashville, Tenn.-based manufacturer of specialty filtration products for industrial lubricants.
  • ONCAP sells medical division to BiomericsJones Day advised ONCAP in the sale by portfolio company Precision Concepts International of its medical division to Biomerics, a portfolio company of Wasatch Equity Partners.
  • Riverside sells Baker Hill to Flexpoint FordJones Day represented The Riverside Company in connection with the sale of portfolio company Baker Hill, a provider of cloud-based, end-to-end loan origination, risk management, and analytics software, to Flexpoint Ford.
  • Cardinal Health merges its Outcomes™ business into Transaction Data SystemsJones Day advised Cardinal Health, Inc. (NYSE: CAH) in connection with the combination of its Outcomes™ business to Transaction Data Systems, a portfolio company of BlackRock Long Term Private Capital and GTCR, in exchange for a minority stake in the combined entity.
    • View All

    October 2024 Commentary

    DOJ and FTC Release Final Rule Expanding HSR Premerger Filing Requirements

    February 2024 Alert

    U.S. Merger Notification Threshold Increases to $119.5 Million

    July 2023 White Paper

    DOJ/FTC Propose Massive Changes to HSR Premerger Filings: What You Need to Know

    January 2023 Alert

    U.S. Merger Notification Threshold Increases to $111.4 Million

    January 2023 Alert

    Congress Enacts Substantial Increase in U.S. Merger Notification Filing Fees for Large Deals

    January 2022 Alert

    U.S. Merger Notification Threshold Increases to $101 Million

    February 2021 Alert

    Antitrust Agencies Suspend Early Termination of HSR Waiting Period

    February 2021 Alert

    U.S. Merger Notification Threshold Falls to $92 Million

    February 2021 Newsletters

    Global Merger Control Update | Winter 2021

    October 2020 External Publications

    Attorney-Client Privilege and Common Interest Privilege in Antitrust Merger Review, The M&A Lawyer, Vol. 24, Issue 9
    View All

    Before sending, please note:

    Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.